UPDATE: Merck (MRK), AstraZeneca (AZN) Report Positive Results from Phase 3 First-Line SOLO-1 Trial for Ovarian Cancer
Tweet Send to a Friend
AstraZeneca (NYSE: AZN) and Merck (NYSE: MRK) today announced positive results from the randomized, double-blinded, placebo-controlled, Phase 3 SOLO-1 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
